ClinicalTrials.gg
CompletedNCT01459367Updated Aug 23, 2013

Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis

A Phase 3 interventional study of TAK-438 and TAK-438 in Erosive Esophagitis, sponsored by Takeda. Completed at 37 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-08-23.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
607
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing vonoprazan in Esophagitis — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Esophagitis.

Enrollment
3rd of 10
607 · median 357
Started
2011
with 1 other
Phase 3
7 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
7 of 10
Takeda

Among the 10 studies testing vonoprazan in Esophagitis, this one is the 3rd largest by enrollment, is one of 2 that started in 2011, is one of 7 in phase 3, and was the 3rd registered.

Esophagitis

123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.

Browse Esophagitis studies →

Open to participants now

1 of the 10 studies testing vonoprazan in Esophagitis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing vonoprazan in Esophagitis, or all of them as a file.
02

Study summary

The purpose of this study is to confirm the efficacy of TAK-438, once daily (QD), compared to lansoprazole for the maintenance treatment of healed erosive esophagitis and to determine the clinical dose.

03

Conditions studied

  • Erosive Esophagitis

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At Visit H-1 (start of the treatment period), the participants must have endoscopically confirmed erosive esophagitis of Grade A to D, as defined by the LA classification grading system, and the target number of participants who are clearly Grade C or D is 15% or more of the total participants.
  2. Outpatients (including inpatient for examination)
  3. Participants must have successfully completed the treatment period and have endoscopically healed EE at Week 2, 4, or 8 in the treatment period. Endoscopically healed EE is defined as those participants who have endoscopically confirmed EE of Grade O as defined by the LA classification grading system.

Exclusion criteria

Exclusion Criteria:

  1. Participants with an esophagus-related complication (eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infection, esophageal stenosis, etc.), a history of radiotherapy or cryotherapy of the esophagus, a caustic or physiochemical trauma (esophageal sclerotherapy, etc.). However, participants with Schatzki's ring (mucosal tissue ring around inferior esophageal sphincter) or Barrett's esophagus are allowed to be included.
  2. Participants who have received surgery or treatment affecting gastroesophageal reflux (cardioplasty, dilation of esophageal stenosis [excluding Schatzki's ring], etc.), or who have a history of surgery of stomach or duodenum (excluding removal of benign polyp under endoscopy)
  3. Participants who have acute upper gastrointestinal bleeding, gastric or duodenal ulcer (mucosal defect with white coating) within 30 days prior to Visit H-1 (initiation of study drug administration). However, participants with gastric or duodenal erosions are allowed to be included.
  4. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorder
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
607 participants (actual)

Study arms

  • Experimental
    TAK-438 10 mg QD

    Drug: TAK-438

  • Experimental
    TAK-438 20 mg QD

    Drug: TAK-438

  • Active comparator
    Lansoprazole 15 mg QD

    Drug: Lansoprazole

Interventions

  • In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks. In the maintenance treatment period, the participants will receive treatment of TAK-438 10 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.

  • In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks. In the maintenance treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.

  • In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks. In the maintenance treatment period, the participants will receive treatment of TAK-438 placebo-matching tablets, orally, once daily and lansoprazole 15 mg, capsules, orally, once daily for up to 24 weeks.

    Also known as: AG-1749

06

What researchers measure

Primary outcomes

  1. Endoscopically confirmed recurrence rate of erosive esophagitis after 24 weeks of maintenance treatment

    Endoscopic recurrence of erosive esophagitis is defined as those participants who have endoscopically confirmed EE of Grade A to D as defined by the Los Angeles (LA) Classification Grading System. The definitions of each grade are: Grade O (No mucosal break), Grade A (Mucosal break \<5 mm), Grade B (Mucosal break ≥5 mm), Grade C (Mucosal break continuous between two or more folds and \<75% of the circumference) and Grade D (Mucosal break ≥75% of the circumference).

    Time frame: 24 Weeks.

Secondary outcomes

  1. Endoscopically confirmed recurrence rate of erosive esophagitis after 12 weeks of maintenance treatment

    Time frame: 12 Weeks.

07

Study locations

37 sites
  • Kashiwa-shi, Chiba, Japan
  • Yachiyo-shi, Chiba, Japan
  • Saijo-shi, Ehime, Japan
  • Fukuoka-shi, Fukuoka, Japan
  • Kasuya-gun, Fukuoka, Japan
  • Koriyama-shi, Fukushima, Japan
  • Takayama-shi, Gifu, Japan
  • Annaka-shi, Gunma, Japan
  • Asahikawa-shi, Hokkaido, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Itami-shi, Hyogo, Japan
  • Kobe-shi, Hyogo, Japan
  • Nishinomiya-shi, Hyogo, Japan
  • Fujisawa-shi, Kanagawa, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Kochi-shi, Kochi, Japan
  • Kumamoto-shi, Kumamoto, Japan
  • Kyoto-shi, Kyoto, Japan
  • Sendai-shi, Miyagi, Japan
  • Nagasaki-shi, Nagasaki, Japan
  • Kishiwada-shi, Osaka, Japan
  • Osaka-shi, Osaka, Japan
  • Suita-shi, Osaka, Japan
  • Takatsuki-shi, Osaka, Japan
  • Saga-shi, Saga, Japan
  • Kumagaya-shi, Saitama, Japan
  • Saitama-shi, Saitama, Japan
  • Tokorozawa-shi, Saitama, Japan
  • Bunkyo-ku, Tokyo, Japan
  • Chuo-ku, Tokyo, Japan
  • Hachioji-shi, Tokyo, Japan
  • Kokubunji-shi, Tokyo, Japan
  • Shibuya-ku, Tokyo, Japan
  • Shinjuku-ku, Tokyo, Japan
  • Toshima-ku, Tokyo, Japan
  • Shimonoseki-shi, Yamaguchi, Japan
  • Tsuru-shi, Yamanashi, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2011
First posted
Oct 25, 2011
Start
Oct 2011
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Last update
Aug 23, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01459367
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 25, 2011
Start date
Oct 2011
Primary completion
Mar 2013
Completion
Mar 2013
Last update
Aug 23, 2013

Study contacts

Senior Manager
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion